Patients under active surveillance for bladder cancer monitoring are currently monitored by invasive and costly cystoscopies.
Urine-based test to monitor for recurrence.
100% negative predictive value.
Attomolar (10^-18) sensitivity.
Can perform in any size urology lab with a simple plate reader. Resuls available in less than an hour.
Patent by international-scope PCT application.
>800,000 people in the US living with bladder cancer present annually up to 3 to 4 times a year for evaluation.
If you have bladder cancer questions, Bladder Cancer Advocacy Network (BCAN) is a wonderful, caring website to visit. EIG has no financial or any affiliation with BCAN.
